GUCY2C ligand replacement to prevent colorectal cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66:7-30; PMID:26742998; http://dx.doi.org/10.1017/S0009840X15002851
   PubMed Web of Science ®Google Scholar
• Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst 2011; 103:117-28; PMID:21228314; http://dx.doi.org/10.1093/jnci/djq495
   PubMed Web of Science ®Google Scholar
• Willyard C. Screening: early alert. Nature 2015; 521:S4-5; PMID:25970456; http://dx.doi.org/10.1038/521S4a
   PubMedGoogle Scholar
• Van Gossum A, Munoz-Navas M, Fernandez-Urien I, Carretero C, Gay G, Delvaux M, Lapalus MG, Ponchon T, Neuhaus H, Philipper M, et al. Capsule endoscopy versus colonoscopy for the detection of polyps and cancer. N Engl J Med 2009; 361:264-70; PMID:19605831; http://dx.doi.org/10.1056/NEJMoa0806347
   PubMed Web of Science ®Google Scholar
• Gravitz L. Prevention: tending the gut. Nature 2015; 521:S6-8; PMID:25970457; http://dx.doi.org/10.1038/521S6a
   PubMedGoogle Scholar
• Drew DA, Cao Y, Chan AT. Aspirin and colorectal cancer: the promise of precision chemoprevention. Nat Rev Cancer 2016; 16(3):173-86; PMID:26868177; http://dx.doi.org/10.1038/nrc.2016.4
   PubMed Web of Science ®Google Scholar
• Carrithers SL, Parkinson SJ, Goldstein S, Park P, Robertson DC, Waldman SA. Escherichia coli heat-stable toxin receptors in human colonic tumors. Gastroenterology 1994; 107:1653-61; PMID:7958675
   PubMed Web of Science ®Google Scholar
• Schulz S, Green CK, Yuen PS, Garbers DL. Guanylyl cyclase is a heat-stable enterotoxin receptor. Cell 1990; 63:941-8; PMID:1701694; http://dx.doi.org/10.1016/0092-8674(90)90497-3
   PubMed Web of Science ®Google Scholar
• Laney DW, Jr., Mann EA, Dellon SC, Perkins DR, Giannella RA, Cohen MB. Novel sites for expression of an Escherichia coli heat-stable enterotoxin receptor in the developing rat. Am J Physiol 1992; 263:G816-21; PMID:1359797
   PubMedGoogle Scholar
• Begg DP, Steinbrecher KA, Mul JD, Chambers AP, Kohli R, Haller A, Cohen MB, Woods SC, Seeley RJ. Effect of guanylate cyclase-C activity on energy and glucose homeostasis. Diabetes 2014; 63(11):3798-804; DB_140160; PMID:24898144; http://dx.doi.org/10.2337/db14-0160
   PubMed Web of Science ®Google Scholar
• Gong R, Ding C, Hu J, Lu Y, Liu F, Mann E, Xu F, Cohen MB, Luo M. Role for the membrane receptor guanylyl cyclase-C in attention deficiency and hyperactive behavior. Science 2011; 333:1642-6; PMID:21835979; http://dx.doi.org/10.1126/science.1207675
   PubMed Web of Science ®Google Scholar
• Valentino MA, Lin JE, Snook AE, Li P, Kim GW, Marszalowicz G, Magee MS, Hyslop T, Schulz S, Waldman SA. A uroguanylin-GUCY2C endocrine axis regulates feeding in mice. J Clin Invest 2011; 121:3578-88; PMID:21865642; http://dx.doi.org/10.1172/JCI57925
   PubMed Web of Science ®Google Scholar
• Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, Chepenik KP, Waldman SA. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 2000; 52:375-414; PMID:10977868
   PubMed Web of Science ®Google Scholar
• Canani RB, Castaldo G, Bacchetta R, Martin MG, Goulet O. Congenital diarrhoeal disorders: advances in this evolving web of inherited enteropathies. Nat Rev Gastroenterol Hepatol 2015; 12:293-302; PMID:25782092; http://dx.doi.org/10.1038/nrgastro.2015.44
   PubMed Web of Science ®Google Scholar
• Donia MS, Fischbach MA. HUMAN MICROBIOTA. Small molecules from the human microbiota. Science 2015; 349:1254766; PMID:26206939; http://dx.doi.org/10.1126/science.1254766
   PubMed Web of Science ®Google Scholar
• Bryant AP, Busby RW, Bartolini WP, Cordero EA, Hannig G, Kessler MM, Pierce CM, Solinga RM, Tobin JV, Mahajan-Miklos S, et al. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci 2010; 86:760-5; PMID:20307554; http://dx.doi.org/10.1016/j.lfs.2010.03.015
   PubMed Web of Science ®Google Scholar
• Schulz S, Lopez MJ, Kuhn M, Garbers DL. Disruption of the guanylyl cyclase-C gene leads to a paradoxical phenotype of viable but heat-stable enterotoxin-resistant mice. J Clin Invest 1997; 100:1590-5; PMID:9294128; http://dx.doi.org/10.1172/JCI119683
   PubMed Web of Science ®Google Scholar
• Li P, Lin JE, Marszlowicz GP, Valentino MA, Chang C, Schulz S, Pitari GM, Waldman SA. GCC signaling in colorectal cancer: Is colorectal cancer a paracrine deficiency syndrome? Drug News Perspect 2009; 22:313-8; PMID:19771320; http://dx.doi.org/10.1358/dnp.2009.22.6.1395254
   PubMedGoogle Scholar
• Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M, Danenberg E, Clarke AR, Sansom OJ, Clevers H. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009; 457:608-11; PMID:19092804; http://dx.doi.org/10.1038/nature07602
   PubMed Web of Science ®Google Scholar
• Brannon AR, Vakiani E, Sylvester BE, Scott SN, McDermott G, Shah RH, Kania K, Viale A, Oschwald DM, Vacic V, et al. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Gen Biol 2014; 15:454; PMID:25164765; http://dx.doi.org/10.1186/s13059-014-0454-7
   PubMed Web of Science ®Google Scholar
• Cheung AF, Carter AM, Kostova KK, Woodruff JF, Crowley D, Bronson RT, Haigis KM, Jacks T. Complete deletion of Apc results in severe polyposis in mice. Oncogene 2010; 29:1857-64; PMID:20010873; http://dx.doi.org/10.1038/onc.2009.457
   PubMed Web of Science ®Google Scholar
• Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 2013; 13:11-26; PMID:23258168; http://dx.doi.org/10.1038/nrc3419
   PubMed Web of Science ®Google Scholar
• Dow LE, O'Rourke KP, Simon J, Tschaharganeh DF, van Es JH, Clevers H, Lowe SW. Apc restoration promotes cellular differentiation and reestablishes crypt homeostasis in colorectal cancer. Cell 2015; 161:1539-52; PMID:26091037; http://dx.doi.org/10.1016/j.cell.2015.05.033
   PubMed Web of Science ®Google Scholar
• Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol 2010; 7:153-62; PMID:20142816; http://dx.doi.org/10.1038/nrclinonc.2009.237
   PubMed Web of Science ®Google Scholar
• Colussi D, Brandi G, Bazzoli F, Ricciardiello L. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci 2013; 14:16365-85; PMID:23965959; http://dx.doi.org/10.3390/ijms140816365
   PubMed Web of Science ®Google Scholar
• Wilson C, Lin JE, Li P, Snook AE, Gong J, Sato T, Liu C, Girondo MA, Rui H, Hyslop T, et al. The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer. Cancer Epidemiol Biomarkers Prevent 2014; 23:2328-37; PMID:25304930; http://dx.doi.org/10.1158/1055-9965.EPI-14-0440
   PubMed Web of Science ®Google Scholar
• Steinbrecher KA, Tuohy TM, Heppner Goss K, Scott MC, Witte DP, Groden J, Cohen MB. Expression of guanylin is downregulated in mouse and human intestinal adenomas. Biochem Biophys Res Commun 2000; 273:225-30; PMID:10873591; http://dx.doi.org/10.1006/bbrc.2000.2917
   PubMed Web of Science ®Google Scholar
• Shailubhai K, Yu HH, Karunanandaa K, Wang JY, Eber SL, Wang Y, Joo NS, Kim HD, Miedema BW, Abbas SZ, et al. Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP. Cancer Res 2000; 60:5151-7; PMID:11016642
   PubMed Web of Science ®Google Scholar
• Pitari GM, Zingman LV, Hodgson DM, Alekseev AE, Kazerounian S, Bienengraeber M, Hajnóczky G, Terzic A, Waldman SA. Bacterial enterotoxins are associated with resistance to colon cancer. Proc Natl Acad Sci USA 2003; 100:2695-9; PMID:12594332; http://dx.doi.org/10.1073/pnas.0434905100
   PubMed Web of Science ®Google Scholar
• Snippert HJ, van der Flier LG, Sato T, van Es JH, van den Born M, Kroon-Veenboer C, Barker N, Klein AM, van Rheenen J, Simons BD, et al. Intestinal crypt homeostasis results from neutral competition between symmetrically dividing Lgr5 stem cells. Cell 2010; 143:134-44; PMID:20887898; http://dx.doi.org/10.1016/j.cell.2010.09.016
   PubMed Web of Science ®Google Scholar
• Ghaleb AM, McConnell BB, Kaestner KH, Yang VW. Altered intestinal epithelial homeostasis in mice with intestine-specific deletion of the Kruppel-like factor 4 gene. Dev Biol 2011; 349:310-20; PMID:21070761; http://dx.doi.org/10.1016/j.ydbio.2010.11.001
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Pitari GM, Di Guglielmo MD, Park J, Schulz S, Waldman SA. Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells. Proc Natl Acad Sci USA 2001; 98:7846-51; PMID:11438734; http://dx.doi.org/10.1073/pnas.141124698
   PubMed Web of Science ®Google Scholar
• Li P, Lin JE, Chervoneva I, Schulz S, Waldman SA, Pitari GM. Homeostatic control of the crypt-villus axis by the bacterial enterotoxin receptor guanylyl cyclase C restricts the proliferating compartment in intestine. Am J Pathol 2007; 171:1847-58; PMID:17974601; http://dx.doi.org/10.2353/ajpath.2007.070198
   PubMed Web of Science ®Google Scholar
• Lin JE, Li P, Snook AE, Schulz S, Dasgupta A, Hyslop TM, Gibbons AV, Marszlowicz G, Pitari GM, Waldman SA. The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling. Gastroenterology 2010; 138:241-54; PMID:19737566; http://dx.doi.org/10.1053/j.gastro.2009.08.064
   PubMed Web of Science ®Google Scholar
• Lin JE, Colon-Gonzalez F, Blomain E, Kim GW, Aing A, Stoecker B, Rock J, Snook AE, Zhan T, Hyslop TM, et al. Obesity-induced colorectal cancer is driven by caloric silencing of the Guanylin-GUCY2C paracrine signaling axis. Cancer Res 2016; 76:339-46; PMID:26773096; http://dx.doi.org/10.1158/0008-5472.CAN-15-1467-T
   PubMed Web of Science ®Google Scholar
• Lin JE, Snook AE, Li P, Stoecker BA, Kim GW, Magee MS, Garcia AV, Valentino MA, Hyslop T, Schulz S, et al. GUCY2C opposes systemic genotoxic tumorigenesis by regulating AKT-dependent intestinal barrier integrity. Plos one 2012; 7:e31686; PMID:22384056; http://dx.doi.org/10.1371/journal.pone.0031686
   PubMed Web of Science ®Google Scholar
• Harris LA, Crowell MD. Linaclotide, a new direction in the treatment of irritable bowel syndrome and chronic constipation. Curr Opin Mole Ther 2007; 9:403-10; PMID:17694454
   PubMed Web of Science ®Google Scholar
• Vazquez Roque M, Camilleri M. Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation. Expert Rev Gastroenterol Hepatol 2011; 5:301-10; PMID:21651347; http://dx.doi.org/10.1586/egh.11.30
   PubMed Web of Science ®Google Scholar
• Videlock EJ, Cheng V, Cremonini F. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis. Clin Gastroenterol Hepatol 2013; 11:1084-92.e3; quiz e68; PMID:23644388; http://dx.doi.org/10.1016/j.cgh.2013.04.032
   PubMed Web of Science ®Google Scholar
• Johnston JM, Shiff SJ, Quigley EM. A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation. Curr Med Res Opin 2013; 29:149-60; PMID:23198977; http://dx.doi.org/10.1185/03007995.2012.754743
   PubMed Web of Science ®Google Scholar
• Quigley EM, Tack J, Chey WD, Rao SS, Fortea J, Falques M, Diaz C, Shiff SJ, Currie MG, Johnston JM. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints. Aliment Pharmacol Ther 2013; 37:49-61; PMID:23116208; http://dx.doi.org/10.1111/apt.12123
   PubMed Web of Science ®Google Scholar
• Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, MacDougall JE, Jia XD, Shao JZ, Fitch DA, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012; 107:1702-12; PMID:22986437; http://dx.doi.org/10.1038/ajg.2012.254
   PubMed Web of Science ®Google Scholar
• Rao S, Lembo AJ, Shiff SJ, Lavins BJ, Currie MG, Jia XD, Shi K, MacDougall JE, Shao JZ, Eng P, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012; 107:1714-24; quiz p 25; PMID:22986440; http://dx.doi.org/10.1038/ajg.2012.255
   PubMed Web of Science ®Google Scholar
• Johnston JM, Kurtz CB, Macdougall JE, Lavins BJ, Currie MG, Fitch DA, O'Dea C, Baird M, Lembo AJ. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology 2010; 139:1877-86.e2; PMID:20801122; http://dx.doi.org/10.1053/j.gastro.2010.08.041
   PubMed Web of Science ®Google Scholar
• Andresen V, Camilleri M, Busciglio IA, Grudell A, Burton D, McKinzie S, Foxx-Orenstein A, Kurtz CB, Sharma V, Johnston JM, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 2007; 133:761-8; PMID:17854590; http://dx.doi.org/10.1053/j.gastro.2007.06.067
   PubMed Web of Science ®Google Scholar
• Castro J, Harrington AM, Hughes PA, Martin CM, Ge P, Shea CM, Jin H, Jacobson S, Hannig G, Mann E, et al. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3′,5prime;-monophosphate. Gastroenterology 2013; 145:1334-46 e1-11; PMID:23958540; http://dx.doi.org/10.1053/j.gastro.2013.08.017
   PubMed Web of Science ®Google Scholar
• Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366:707-14; PMID:22356324; http://dx.doi.org/10.1056/NEJMoa1112302
   PubMed Web of Science ®Google Scholar
• Carter CA, Kelly RJ, Giaccone G. Small-molecule inhibitors of the human epidermal receptor family. Expert Opin Invest Drugs 2009; 18:1829-42; PMID:19938898; http://dx.doi.org/10.1517/13543780903373343
   PubMed Web of Science ®Google Scholar
• Solinga RKM, Busby R, Currie M. A comparison of the physical and pharmacological properties of plecanatide (SP-304) and the human hormone uroguanylin. ACJ 2011; 11:332
   Google Scholar
• Shailubhai KLB, Talluto C, Comiskey S, Foss J, Feng R, Joslyn A, Jacob G. Plecanatide, a guanylate cyclase C agonist, improves bowel habits and symptoms associated with chronic constipation in a phase IIa clinical study. ACJ 2011; 11:1174
   Google Scholar
• Graham Zhang KPA, Foss JA, Comiskey SJ, Shailubhai K. SP-333, a proteolysis-resistant agonist of guanylate cyclase-C, inhibits activation of NF-κB and suppresses production of inflammatory cytokines to ameliorate DSS-induced colitis in mice. 77th annual meeting of American College of Gastroenterology.
   Google Scholar
• SynergyPharmaceuticals. Pipeline: SP-333. http://www.synergypharmacom/pipeline/sp-333 2013.
   Google Scholar
• SynergyPharmaceuticals. Single ascending dose study to evaluate the safety, tolerability and pharmacokinetics (PK) of SP-333 tablets in healthy adult subjects. ClinicalTrialsgov; Identifier: NCT01705938.
   Google Scholar
• Steinbrecher KA, Wowk SA, Rudolph JA, Witte DP, Cohen MB. Targeted inactivation of the mouse guanylin gene results in altered dynamics of colonic epithelial proliferation. Am J Pathol 2002; 161:2169-78; PMID:12466132; http://dx.doi.org/10.1016/S0002-9440(10)64494-X
   PubMed Web of Science ®Google Scholar
• Li P, Schulz S, Bombonati A, Palazzo JP, Hyslop TM, Xu Y, Baran AA, Siracusa LD, Pitari GM, Waldman SA. Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity. Gastroenterology 2007; 133:599-607; PMID:17681179; http://dx.doi.org/10.1053/j.gastro.2007.05.052
   PubMed Web of Science ®Google Scholar
• Han X, Mann E, Gilbert S, Guan Y, Steinbrecher KA, Montrose MH, Cohen MB. Loss of guanylyl cyclase C (GCC) signaling leads to dysfunctional intestinal barrier. PloS One 2011; 6:e16139; PMID:21305056; http://dx.doi.org/10.1371/journal.pone.0016139
   PubMed Web of Science ®Google Scholar
• Lubbe WJ, Zuzga DS, Zhou Z, Fu W, Pelta-Heller J, Muschel RJ, Waldman SA, Pitari GM. Guanylyl cyclase C prevents colon cancer metastasis by regulating tumor epithelial cell matrix metalloproteinase-9. Cancer Res 2009; 69:3529-36; PMID:19336567; http://dx.doi.org/10.1158/0008-5472.CAN-09-0067
   PubMed Web of Science ®Google Scholar
• Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 2009; 22:191-7; PMID:21037809; http://dx.doi.org/10.1055/s-0029-1242458
   PubMedGoogle Scholar
• Harmel-Laws E, Mann EA, Cohen MB, Steinbrecher KA. Guanylate cyclase C deficiency causes severe inflammation in a murine model of spontaneous colitis. PloS One 2013; 8:e79180; PMID:24244444; http://dx.doi.org/10.1371
   PubMed Web of Science ®Google Scholar
• Brenna O, Bruland T, Furnes MW, Granlund A, Drozdov I, Emgard J, Brønstad G, Kidd M, Sandvik AK, Gustafsson BI. The guanylate cyclase-C signaling pathway is down-regulated in inflammatory bowel disease. Scand J Gastroenterol 2015; 50:1241-52; PMID:25979109; http://dx.doi.org/10.3109/00365521.2015.1038849
   PubMed Web of Science ®Google Scholar
• Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 2011; 60:397-411; PMID:21036793; http://dx.doi.org/10.1136/gut.2010.217182
   PubMed Web of Science ®Google Scholar
• Ogino S, Lochhead P, Chan AT, Nishihara R, Cho E, Wolpin BM, Meyerhardt JA, Meissner A, Schernhammer ES, Fuchs CS, et al. Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol 2013; 26:465-84; PMID:23307060; http://dx.doi.org/10.1038/modpathol.2012.214
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29; PMID:22237781; http://dx.doi.org/10.1017/S0009840X11002678
   PubMed Web of Science ®Google Scholar
• Kaitin KI. Deconstructing the drug development process: the new face of innovation. Clin Pharmacol Ther 2010; 87:356-61; PMID:20130565; http://dx.doi.org/10.1038/clpt.2009.293
   PubMed Web of Science ®Google Scholar